67310-57-0

Usage

InChI:InChI=1/C8H8O4/c9-5-7-2-1-6(12-7)3-4-8(10)11/h1-4,9H,5H2,(H,10,11)/b4-3+

Upstream product

• 67-47-0 5-hydroxymethyl-2-furfuraldehyde 
• 141-82-2 malonic acid 
• 470-23-5 D-fructose 
• 20079-34-9 methyl (E)-3-(5-(hydroxymethyl)furan-2-yl)acrylate 

Relevant academic research and scientific papers

Lipase-Catalyzed Synthesis of Furan-Based Oligoesters and their Self-Assembly-Assisted Polymerization

We investigate the synthesis of bio-based hydrophilic and hydrophobic oligoesters, which in turn are derived from easily accessible monomers from natural resources. In addition to the selection of renewable monomers, Novozyme 435, an immobilized lipase B from Candida antarctica was used for the oligomerization of monomers. The reaction conditions for oligomerization using Novozyme 435 were established to obtain a moderate-to-good yield. The average number of repeating units and the molecular weight distribution of hydrophilic and hydrophobic oligoester were identified by using NMR spectroscopy, gel-permeation chromatography, and MS. The oligoester derived from a hydrophilic monomer self-assembled to form a viscous solution, which upon further heating resulted in the formation of a polymer by the intermolecular Diels–Alder reaction. The viscosity of the solution and the assembly of oligoester to form a fibrous structure were investigated by using rheological studies, XRD, and SEM. The molecular weight of the cross-linked polymer was identified by using matrix-assisted laser desorption/ionization–MS. The thermal properties of the bio-based polymers were investigated by using thermogravimetric analysis and differential scanning calorimetry. For the first time, the self-assembly-assisted polymerization of an oligoester is reported using the intermolecular Diels–Alder reaction, which opens a new avenue in the field of polymer science.

Metabolically stable 5-HMF derivatives for the treatment of hypoxia

5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.